We currently face an alarming resurgence in infectious diseases characterized by antimicrobial resistance and therapeutic failure. This has generated the urgent need of developing new therapeutic approaches that include agents with nontraditional modes of action. A recent interest focused on approaches based on our natural immune defenses, especially on peptides that combine innate antimicrobial activity against diverse pathogens and immunoregulatory functions. In this study, to our knowledge, we describe for the first time the antimicrobial activity of the neuropeptide urocortin II (UCNII) against a panel of Gram-positive and Gramnegative bacteria and tropical parasites of the genus Leishmania. Importantly, this cytotoxicity was selective for pathogens, because UCNII did not affect mammalian cell viability. Structurally, UCNII has a cationic and amphipathic design that resembles antimicrobial peptides. Using mutants and UCNII fragments, we determined the structural requirements for the interaction between the peptide and the surface of pathogen. Following its binding to pathogen, UCNII caused cell death through different membrane-disrupting mechanisms that involve aggregation and membrane depolarization in bacteria and pore formation in Leishmania. Noteworthily, UCNII killed the infective form of Leishmania major even inside the infected macrophages. Consequently, UCNII prevented mortality caused by polymicrobial sepsis and ameliorated pathological signs of cutaneous leishmaniasis. Besides its presence in body physical and mucosal barriers, we found that innate immune cells produce UCNII in response to infections. Therefore, UCNII could be considered as an ancient highly-conserved host peptide involved in the natural antimicrobial defense and emerge as an attractive alternative to current treatments for microbial disorders with associated drug resistances.
L iving organisms are continuously faced with pathogens that disrupt homeostatic conditions in the body and lead to different infectious diseases. In the poorest areas worldwide, neglected tropical diseases caused by trypanosomatid parasites affect .1 billion people (1) . Similarly, sepsis affects 18 million people in the richest countries, where it is the third leading cause of death (with mortality rates of 28-47%) as a consequence of the uncontrolled systemic immune response to bacterial infections (2) . What tropical parasitic diseases and sepsis have in common is that they may cause multisystemic damage and that available drugs are ineffective, toxic, and susceptible to resistance. Identification of new agents with nontraditional modes of action is critical for the design of more efficient therapeutic strategies.
A global interest in the development of novel strategies that take advantage of our natural immune defenses has lately emerged (3), and current approaches are focused on the characterization of the so-called host defense peptides (HDP). HDP are evolutionary ancient molecules that reinforce the human immune system against microbial invasion by combining inherent antimicrobial activities on diverse pathogens with regulatory functions that potentiate innate immunity (4, 5) .
HDP are present in all organisms along the phylogeny, from single-cell microorganisms to mammals, including humans. Although HDP conform a structurally diverse group of molecules that form a-helices, b-sheets, mixture of a-helices/b-sheets, cyclic, as well as extended and flexible loops (6) , they share some common characteristics. They are short (10-50 aa) peptides with a frequent overall positive charge (generally +2 to +9) and a substantial proportion ($30%) of hydrophobic residues, which allow them to fold into an amphiphilic structure, often upon contact with biological membranes (7, 8) . These structural characteristics support the selective targeting of HDP for pathogens versus mammalian cells, which present different lipid and polysaccharide compositions, fluidity, and charge in their membranes (9) . Moreover, HDP are constitutively expressed by phagocytic cells of the immune system and by many body tissues, particularly at interfaces between the environment and the host, such as skin and mucosal membranes (10) . Furthermore, stress and danger signals, including microbial products, cytokines, and neuroendocrine factors, induce the release of HDP. Recent evidence indicates that some neuropeptides exert important antimicrobial activities (11) , although the involved mechanisms remain largely unclear. Neuropeptides are pleiotropic and integral components of the neuroendocrine system. Although their roles are traditionally related to signaling and modulation in the central and peripheral nervous systems, some neuropeptides exert additional functions as components of the innate immune response and participate in the bidirectional cross-talk that exists between the immune and neuroendocrine systems (12) . Among them, urocortins (UCNs) are some of the most evolutionary ancient neuropeptides (13) . UCNs are structurally and functionally related to the corticotrophin-releasing factor (CRH) family and include UCNI, UCNII, UCNIII, urotensin 1 (only present in fishes), and sauvagine (only present in amphibians) (14) . UCNs are widely distributed in the nervous, cardiovascular, reproductive, and immune systems, and are mainly involved in responses to psychological, osmotic, and ionic stress (15) . Regarding the immune system, UCNI acts as a potent anti-inflammatory factor (opposite to the proinflammatory role of CRH) and exerts potent therapeutic effects in various inflammatory and autoimmune disorders (16) (17) (18) (19) (20) . Interestingly, UCNI and UCNII share some structural characteristics with antimicrobial peptides. They are small peptides with a-helical structure and amphipathic properties (Fig. 1A) , are present in primitive organisms, and are produced by epithelial and mucosal surfaces (21, 22) . Indeed, we previously reported the trypanolytic effect of UCNI against the bloodstream form of Trypanosome brucei, the causing agent of sleeping sickness (23) . The present study describes that UCNII, but not UCNI, shows potent antimicrobial activities against various bacterial strains and protozoa parasites belonging to the Leishmania genus. The killing activity of UCNII was exerted through a selective binding to the surface of the pathogens and targeting of critical structures for microbes. Moreover, UCNII acts as a true HDP released by immune cells in response to infection. Finally, we demonstrated the therapeutic application of UCNII in experimental models of sepsis and cutaneous leishmaniasis. In summary, we identify a new role for UCNII as an endogenous component of the immune innate defense system.
Materials and Methods

Peptides
UCNI and UCNII were purchased from American Peptide. Fragments derived from the original sequence of UCNII (UCNII , UCNII [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , UCNII , UCNII , and UCNII [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] ) and FITC-labeled UCNII were designed by our group and chemically synthesized by GeneScript. Peptides were initially reconstituted at 10 24 M (final pH 2.5) in ultrapure water (Bio-Rad) under sterile conditions, and then dissolved in PBS (1.2 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 , 130 mM NaCl, 2.6 mM KCl [pH 7.0]) or the corresponding culture medium (final pH 7.4) at the indicated concentrations before their use.
Pathogens and growth conditions
Escherichia coli Top10 (Invitrogen, Carlsbad, CA) and E. coli K-12 mutants deficient in LPS synthesis (E. coli Genetic Stock Center, Yale University, New Haven, CT) were cultured under shaking in Luria Broth medium at 37˚C. Streptococcus mutans (CECT 479), Micrococcus luteus (CECT 243), and Pseudomonas pseudoalcaligenes (CECT 318), all obtained from the Spanish Center for Type Culture Collection, were grown under shaking in brain heart infusion broth (Difco Laboratory, Detroit, MI) at 37˚C, in Nutrient I at 30˚C, and in Nutrient II at 26˚C, respectively.
Leishmania major Friedlin (MHOM/IL/80/Friedlin) clone V1, lipophosphoglycan-inducible mutant glf 2/+ KiddGLF L. major (24), phosphoglycan-deficient lpg2 2/2 L. major (25), L. major LV39 clone 5 (Rho/ SU/59/P), and Leishmania donovani (MHOM/ET/67/HU3) promastigotes were cultured at 28˚C in M-199 medium (Invitrogen) supplemented with 40 mM HEPES, 100 mM adenosine, 0.77 mM hemin, 10 mM biopterin, and 10% FBS. Promastigotes of Leishmania infantum (MHOM/ES/1993/BCN-99), Leishmania tropica 656 cl (MHOM/IS/1998/LRC), and Leishmania mexicana (MHOM/VE/1990/M9012) were cultured in modified RPMI 1640 medium (Invitrogen) supplemented with 20% FBS at 28˚C (L. infantum and L. tropica) or 23˚C (L. mexicana).
Antimicrobial assays
To determine the bactericidal activity, each bacterial strain (10 6 cells, midexponential growth phase) was incubated with UCNI, UCNII, and UCNII-derived fragments (5 mM, unless other concentration is indicated) in 100 ml PBS for 3 h, under shaking at the indicated growth temperatures. We stopped the reaction by adding cold PBS (dilution 1/100) on ice for 5 min, and then we determined the number of CFU/ml after overnight incubation on agar dishes. Results were expressed as percentage of bacterial survival (CFUs after peptide treatment/CFUs in absence of peptide) 3 100. Where indicated, we adjusted the pH of PBS to acid (pH 6.0) or basic (pH 8.0) conditions. To elucidate the effects of NaCl and MgCl 2 in the bactericidal activity of UCNII, the bacteria-peptide reaction solution consisted in PBS supplemented with 20 or 50 mM NaCl or with 1 or 50 mM MgCl 2 .
To determine the antimicrobial activity of the peptides on Leishmania promastigotes, we used the Alamar Blue reagent (Sigma-Aldrich), as described (26) . Briefly, parasites were harvested at late exponential phase and incubated in 96-well plates (100 ml/well, 2.5 3 10 5 cells/ml) with UCNI, UCNII, or UCNII-derived fragments (12 mM, unless indicated) at specified growth temperatures. Peptides were also added at 24 h of culture. Where indicated, we adjusted the pH of culture media to pH 6.0 or pH 8.0. After 72 h of incubation, Alamar Blue (0.11 mg/ml, 20 ml/well) was added to cultures for 4 h and solubilized with 100 ml 3% SDS. Cell viability was assayed using a fluorescent plate reader (550 nm excitation, 590 nm emission).
Determination of changes in plasma membrane potential and permeabilization
We used bisoxonol (Molecular Probes), a potentially sensitive anionic dye that increases fluorescence after its insertion into the depolarized membrane to monitor changes in plasma membrane potential. E. coli (5 3 10 6 ) were cultured in 100 ml PBS at 37˚C for 1 h in the absence or presence of 10 mM UCNII, and log-phase L. major promastigotes (2 3 10 6 ) were cultured in 100 ml HPMI buffer (20 mM HEPES, 132 mM NaCl, 3.5 mM KCl, 0.5 mM MgCl 2 , 5 mM glucose, 1 mM CaCl 2 [pH 7.4]) in the absence or presence of 12 mM UCNII for different time periods at 28˚C. Then bacteria and parasites were incubated with 0.025 mM bisoxonol for 10 min at room temperature. Fluorescence changes were monitored using a fluorescent plate reader (544 nm excitation, 584 nm emission). We used heated bacteria (10 min at 80˚C) and parasites treated with 0.8 mM gramicidin D as controls of maximal membrane depolarization.
We used SYTOX Green (m.w. = 600; Molecular Probes) to evaluate changes in the permeability of the plasma membrane. E. coli and L. major pretreated with UCNII, as described above, were incubated with SYTOX Green (0.05 mM for bacteria, 2 mM for parasite) at room temperature. After 10 min, we measured the increase in fluorescence (485 nm excitation, 520 nm emission) that reflects substantial damage of plasma membrane. We used heated bacteria (10 min, 80˚C) or 0.1% Triton X-100-treated parasites as controls of maximal membrane permeabilization.
Electron microscopy E. coli (10 6 , incubated with 5 mM UCNII at 37˚C) or log-phase L. major promastigotes (5 3 10 6 , incubated with 12 mM UCNII at 28˚C) were harvested by centrifugation (2000 3 g, 15 min, at 4˚C) after different time periods and then subjected to the High Pressure Freezing method (27) and embedded in Lowicryl HM20 resin. Ultrathin cryosections (65 nm) were stained with 2% uranyl acetate (pH 7.0), collected with 2% methylcellulose/ 4% uranyl acetate (pH 7.0), and observed in a JEM-1010 electron microscope (Jeol).
Determination of ATP levels
Log-phase L. major (2 3 10 6 ) were treated with 12 mM UCNII in HPMI buffer, as described above, and mixed with 50 ml CellTiter-Glo reagent (Promega). After 10 min at room temperature, luminescence signal, proportional to the ATP amount, was monitored by an Infinite F200 microplate reader. We used parasites incubated with 10 mM sodium azide, 5 mM 2-deoxyglucose, and 5 mM pyruvate as a control of ATP deprivation. ATP levels in bacteria cultures were determined by luminescence using the BacTiter-Glo microbial cell viability kit (Promega) following the manufacturer's instructions.
Assay of binding of UCNII to pathogens
To determine binding capacity of UCNII to both pathogens, we cotreated 10 7 L. major with 8 mM UCNII and 4 mM FITC-labeled UCNII in HPMI buffer or 5 3 10 6 E. coli with 3 mM UCNII and 2 mM FITC-labeled UCNII in PBS. After different periods of incubation, cells were washed with cold PBS, fixed in 2% formaldehyde, and mounted in DAPI-containing ProLong medium. Images were acquired in a fluorescence microscope (Olympus IX81) and then deconvolved using Huygens Professional program (Scientific Volume Imaging).
In vivo experimental models
Female BALB/c mice (6-8 wk old; Charles River) were used in all experiments. Animal experimental protocols were performed according to the National/European Union Guidelines for the Care and Use of Laboratory Animals in Research and approved by the Experimental Animal Committee of the University of Seville and by the Ethics Committee of the Spanish Council of Scientific Research (file P09-CTS-4705).
To induce sepsis, cecum of anesthetized mice was ligated 5.0 mm from the cecal tip and punctured once with a 22-gauge needle. PBS (controls) or UCNII (1 nmol in 100 ml PBS) were administered i.p. at 1, 12, and 24 h after cecal ligation and puncture (CLP). The effective concentrations of UCNII used in the study were chosen based on previous experiments performed in our laboratory and corresponded approximately to 10 mM. Animals were monitored daily for survival and clinical signs. Sera and peritoneal fluid were collected by cardiac puncture and peritoneal lavage, respectively, 6 and 24 h post-CLP. The bacterial load in peritoneal fluid and sera was determined by dilution plating onto trypticase soy agar with 5% sheep blood (BD Biosciences) and CFU counting after overnight incubation. Peritoneal exudates and sera were also assayed for cytokine/chemokine contents by a specific sandwich ELISA (BD Pharmingen and PeproTech).
To induce cutaneous leishmaniasis, mice were injected s.c. in the left hind footpads with 10 4 L. major purified metacyclic promastigotes isolated from stationary cultures by negative selection with peanut agglutinin, as described below. PBS or UCNII (1.5 nmol/mouse, 3 times per week) were administered s.c. in the infected footpad for 7 wk starting 2 wk postinfection. Disease progression was monitored by measuring the inflammatory edema and the area of the cutaneous lesion of the infected footpad using a digital caliper. Values obtained in the uninfected contralateral footpad were used as reference. Parasite burden was determined 7 wk postinfection by the presence of viable parasites in homogenates of footpad, spleen, and lymph nodes resuspended in culture medium (modified RPMI 1640 medium supplemented with 20% FBS) using a limiting dilution assay (28) . Briefly, 12-24 serial 10-fold dilutions of the nonsedimented fraction of the homogenates were seeded on flat-bottom 96-well plates and incubated at 28˚C during 7-10 d to allow transformation of amastigotes into promastigotes. We then determined the number of positive wells (presence of motile parasites) and negative wells using an inverted microscope, and parasite burden was the highest dilution yielding growth of viable parasites. For histological analysis, paws were fixed in 4% buffered formaldehyde, decalcified in Bouin Liquor DC, and paraffin embedded, and sections were stained with HE.
Purification of metacyclic parasites
Stationary-phase L. major promastigotes (10 8 ) were collected after 4 d in culture, washed with fresh supplemented M199 medium, and incubated with 100 mg peanut agglutinin (Vector) for 15 min at room temperature. Cells were separated by centrifugation (500 3 g, 10 min, 4˚C), and the nonagglutinated metacyclic promastigotes were collected from the supernatant and diluted at 2.5 3 10 5 cells/ml in PBS supplemented with 0.5 mM MgCl 2 and 1 mM CaCl 2 .
Determination of macrophage infection by amastigotes
To determine the effect of UCNII in the capacity of infection of L. major in vitro, macrophages (5 3 10 5 ) obtained from peritoneal lavage of BALB/ c mice were seeded on coverslips in 24-well plates and allowed to adhere overnight at 37˚C. After washing, macrophages were infected with stationary-phase L. major promastigotes transfected with a plasmidexpressing red fluorescent protein (pNUS-mRFPcD) at a parasite:macrophage ratio of 10:1 in RPMI 1640 complete medium supplemented with 5% FBS at 35˚C in the absence or presence of UCNII (12 mM). After 4 h, nonengulfed parasites were washed away and macrophages were further incubated in 10% FBS-supplemented RPMI 1640 complete medium for 48 h (37˚C, 5% CO 2 ) in the presence of LPS (100 ng/ml) and IFN-g (5 ng/ml) in the absence or presence of UCNII (12 mM). In another set of experiments, macrophages were incubated with LPS plus IFN-g and with UCNII (12 mM) in the absence of parasites for 48 h (37˚C, 5% CO 2 ).
To determine the target of UCNII, infected macrophages were incubated with 8 mM UCNII plus 4 mM FITC-labeled UCNII. At different time periods, coverslips with infected macrophages were PBS washed twice, fixed with 2% paraformaldehyde/glucose, mounted in DAPI-containing ProLong, and observed in an Olympus IX81 fluorescence microscope, and the number of infected macrophages and of parasites was determined using Image J software. 
Measurement of UCNII content
The content of UCNII in serum, peritoneal fluid, and supernatants of macrophages stimulated with different stimuli (LPS, E. coli, L. major) was determined by using a specific ELISA kit (Uscn Life Science; minimum detectable UCNII concentration was 2.5 ng/ml).
Statistical analysis
All data are expressed as the mean 6 SEM. Statistical analysis was carried out using Student t test. We assumed significance at p , 0.05.
Results
UCNII, but not UCNI, shows potent bactericidal activity
Although database and bioinformatic tools of prediction of secondary structures classified UCNI and UCNII as all-a-helix peptides with amphipathic properties (Supplemental Table I , Fig. 1A) , only UCNII shows a clear cationic nature and high positive hydrophobicity index (Supplemental Table I ). Indeed, the structural profile for UCNII fits to a potential antimicrobial peptide with a central cationic cluster flanked by two hydrophobic domains (Nterminal and C-terminal). Accordingly, UCNII, but not UCNI, had significant antimicrobial activities against Gram-negative (E. coli, P. pseudoalcaligenes) and Gram-positive (M. luteus) bacterial strains, showing EC 50 values ,5 mM (Fig. 1B, Table I ). However, UCNII failed against other Gram-positive bacteria such as S. mutans (Table I ). The lack of recovery of bacterial viability after removal of UCNII indicates that the neuropeptide is bactericidal as opposed to bacteriostatic.
For a future therapeutic application, it is essential to confirm the selectivity of the antimicrobial peptide for pathogens and that it is not toxic for mammalian cells. Toxicity and hemolytic assays indicated that UCNII neither affected significantly the viability of mouse primary macrophages and splenocytes (90.9 6 1.2% and 93.5 6 1.3% of survival, respectively) nor lysed erythrocytes (3.0 6 0.2% of hemolysis) at the highest concentration assayed in this study (12 mM) .
UCNII disrupts the integrity of plasma membrane of bacteria
We further investigated the potential mechanisms involved in the bactericidal effect of UCNII. To this purpose, we used E. coli because the higher susceptibility of Gram-negative bacteria to UCNII, the accessibility to mutants of this strain, and Gram-negative bacteria are the major cause of sepsis (an experimental model later used in our study). Most of cationic antimicrobial peptides target the bacteria through electrostatic interactions with plasma membrane, formation of transmembrane pores, and loss of membrane integrity that causes cell death. By using FITC-labeled UCNII, we observed that UCNII rapidly targeted the bacterial surface and exerted an agglutinating effect that affected the gross morphology of the bacteria (Fig. 1C) . Ultrastructural analysis showed that, whereas the inner and outer plasma membranes are continuous structures in E. coli, the cytoplasmic membrane appeared to be retracted from the outer membrane in UCNII-treated bacteria (Fig. 1D) , suggesting that UCNII affects the integrity of the plasma membrane. To further investigate this possibility, we performed two complementary approaches. First, we monitored membrane depolarization by using the bisoxonol dye, a lipophilic anion that enters into membranes only if their potential has collapsed. Second, we tested the access to the cytosol of the vital dye SYTOX Green, which requires large-size lesions in the membrane to enter into the cell, being precluded in intact cells. UCNII-treated bacteria increased the uptake of bisoxonol (Fig. 1E, left) , but not of SYTOX (Fig. 1E, right) , supporting an effect in membrane depolarization without the induction of big lesions in the membrane. This agrees with the ultrastructural images, which did not show visible pores in the membrane of UCNII-treated bacteria (Fig. 1D) . Moreover, plasma membrane disruption by UCNII induced a significant depletion in bacterial ATP levels (Fig. 1F) .
Determinants influencing antibacterial activity of UCNII
Antimicrobial peptides are strongly influenced by the ionic strength and pH of the medium as well as the structural requirements of the molecule. To address the first issue, we investigated the effect of NaCl and MgCl 2 on the bactericidal effect of UCNII. UCNII fully kept the antimicrobial activity in the presence of physiological concentrations of NaCl (150 mM) and divalent cations (1 mM Mg 2+ ) (data not shown). However, its bactericidal action was slightly attenuated by the addition of 180 mM NaCl and entirely abolished in the presence of 50 mM MgCl 2 ( Fig. 2A) . The salt-dependent antibacterial activity of UCNII suggests that initial electrostatic interactions between the peptide and bacterial targets play a critical role. Moreover, the antibacterial activity of UCNII was partially abrogated by decreasing the pH of the medium (Fig. 2B) .
To determine the structural requirements of UCNII in the bactericidal effect, we designed various fragments of the native peptide, each of them containing potential critical domains in the molecule according to differences in hydrophobicity, a-helix percentage, and net charge (Supplemental Table I ). UCNII-derived fragments comprising the first 17 N-terminal aa (UCNII [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ) or the last 11 or 20 C-terminal residues (UCNII [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] or UCNII were completely ineffective against E. coli (Fig. 2C) . Only the fragment containing the first 26 N-terminal aa of the native peptide kept some bactericidal activity (Fig. 2C) . This suggests that the rate, conformational orientation, and intramolecular relationship between positive charges and hydrophobic residues in molecule are determinant for the bactericidal effect of UCNII.
Because LPS is the main outer membrane component of Gramnegative bacteria and modulates the antimicrobial activity of other compounds (29, 30) , we next investigated its role in the antimicrobial effect of UCNII. We tested the effect of UCNII in five mutant strains derived from E. coli K-12 D21 that are differentially defective on various components of the LPS molecule (Fig.  2D) . Interestingly, the D21f2"Rd" strain (that only retains the 3-deoxy-D-manno-octulosonic acid, Kdo) was the unique mutant strain that was fully resistant to UCNII (Fig. 2E , Supplemental Table II ). These data suggest that the LPS domain containing heptoses is essential for the bactericidal effect. Indeed, simulations of docking of UCNII and LPS showed a good affinity for the complex (211.31 6 0.15 kcal/mol) and that UCNII interacts mainly with the branches of the polysaccharide moiety at the interface with the lipid portion of LPS (Fig. 2F, Supplemental Video 1) . This interaction seems to involve mainly the cationic and Nterminal domains of UCNII. Docking models predicted specific hydrogen-bonding contacts with LPS for at least 14 residues of UCNII, being especially important for Val 1 fragment that is essential for killing bacteria (Fig. 2C) . Interestingly, the two identified LPSinteracting clusters bind with the same surface of UCNII, which concentrates the cationic residues orientated in that side of the molecule (Fig. 2F, Supplemental Video 2) . The affinity for the docking using D21f1"Rd" mutant containing the Kdo and heptose residues (29.18 6 0.12 kcal/mol) was similar to that showed for The Journal of Immunologythe entire LPS core. However, the simulated energy of binding of UCNII to Kdo domain decreased significantly (28.11 6 0.07 kcal/mol, p , 0.001 versus D21f1"Rd" mutant). Together, these data indicate that, although UCNII needs to interact with the entire LPS structure to ensure bacterial killing, the sugar domain containing the heptose moieties is essential.
Electron microscopy analysis of UCN-treated bacteria (Fig. 1D ) showed electrodense material surrounding bacteria, suggesting that UCNII could form macromolecular aggregates. Experiments with FITC-labeled UCNII confirmed the formation of these visible aggregates (Fig. 1C) . Spectrophotometry, light microscopy, and molecular docking simulation confirmed that UCNII naturally aggregates at physiological pH, but not at acidic pH (Supplemental Fig. 1, Supplemental Videos 3 and 4) . The fact that acidification of media below the physiological pH partially reversed the antibacterial activity of UCNII (Fig. 2B) supports the importance of the aggregation of the peptide in its bactericidal effect. Interestingly, removal of the C-terminal domain diminishes significantly the formation of peptide aggregates (affinity for the complex UCNII-UCNII, 27.21 6 0.07; affinity for the complex of UCNII 1-26 , 25.62 6 0.12, p , 0.001).
UCNII protects against polymicrobial sepsis
We next studied the potential therapeutic effect of UCNII in a preclinical model of polymicrobial sepsis. Untreated animals rapidly died as a consequence of the cecal perforation (Fig. 3A) , which leads to a focal peritoneal infection that subsequently becomes systemic (Fig. 3B) . Host responded to infection by increasing the local and systemic secretion of cytotoxic factors, inflammatory cytokines, and chemokines by immune cells (Fig.  3C) , which cause inflammatory infiltration, tissue damage, and disseminated coagulation in target organs (Supplemental Fig. 2A) , and subsequently, the multiorgan failure characteristic of sepsis. Intraperitoneal injection of UCNII to septic animals significantly increased the survival and reduced bacterial loads, inflammatory mediators, and the histopathologic alterations associated with sepsis ( Fig. 3, Supplemental Fig. 2A ). This protective effect seems to be primarily mediated through a local bactericidal effect of UCNII. To support this hypothesis, we performed additional experiments that discard other possibilities. First, we found that UCNII did not significantly affect the production of inflammatory mediators necessary to kill pathogens by macrophages activated with bacterial endotoxin or infected with E. coli (Supplemental Fig. 2B, 2C) . Moreover, UCNII treatment did not increase the phagocytosis of E. coli by macrophages (data not shown). Second, UCNII did not protect against a severe form of endotoxemia caused by a Gram-negative bacterial product (LPS), which causes exacerbated systemic inflammation and multiorgan failure in a bacteria-free system (Supplemental Fig. 2D ). Similarly, UCNII 50 (mM) represents the concentration of the peptide that reduces to 50% the viability of each parasite. EC 50 was calculated using four-parameter logistic curvefitting software (SigmaPlot). Data show mean 6 SEM of four independent experiments, performed in duplicate.
failed to prevent colitis and death caused by bowel inflammation in absence of infection (Supplemental Fig. 2E ). These data support that UCNII needs to neutralize the whole living bacteria to protect from sepsis.
Cytotoxic activity of UCNII on promastigotes of Leishmania
We next investigated whether the antimicrobial effect of UCNII could be extended to tropical trypanosomatid parasites. Among them, Leishmania represents a global health problem in the absence of adequate control measures and effective drug treatments. The parasite is an obligate intracellular organism with a digenetic life cycle alternating between the flagellated, extracellular promastigote form in the digestive tract of the sandfly vectors, and the amastigote infective form that lives inside mammalian phagocytes. Importantly, Leishmania species are characterized by a high negative glycocalix that makes them attractive targets for antimicrobial peptides (31) . We observed that UCNII, but not UCNI, significantly reduced viability of promastigote forms of different species of Leishmania (Fig. 4A, Table II) , including those that are associated with cutaneous (L. major) and visceral (L. infantum) manifestations of leishmaniasis. We selected L. major to characterize the mechanisms involved in the leishmanicidal actions of UCNII, due to the availability of experimental tools for its study and because it is the form that causes cutaneous leishmaniasis (an experimental model further used in this study).
UCNII induces the formation of pores in the plasma membrane of Leishmania
We observed that the peptide quickly bound to the whole parasite surface, induced a disorganization of the parasite structure (round morphology and loss of the flagellum), and caused leakage of the cellular content (Fig. 4B) . UCNII induced a rapid dissipation of the membrane potential of L. major promastigotes (Fig. 4C, upper  panel) and increased the permeabilization of the plasma membrane through a mechanism that involves formation of lesions of large size (Fig. 4C, lower panel) . Electron microscopy showed a severe disruption of the membrane structure in the peptidetreated parasites, and the formation of pores, accompanied by a loss of electron-dense intracytoplasmic material (Fig. 4D) . This leads to a collapse of the bioenergetic metabolism of the parasite, monitored by a decrease in intracellular ATP levels (Fig. 4E) , and by alterations in mitochondrial membrane potential (43.8 6 2.5% of Rho123 incorporation, p , 0.0001 versus untreated parasites).
To investigate potential targets for UCNII in the parasite, we consider lipophosphoglycan (LPG), a main strongly anionic component of the glycocalix of Leishmania promastigotes. This molecule has some structural analogy to bacterial LPS in containing a repeating phosphoglycan (PG) unit (Gal-Man-P) anchored by a glycan core to a phosphatidylinositol anchor (32) . Additionally, promastigote and amastigote parasites express proteophosphoglycans, a mucin-like protein modified by the PG repeats. We addressed the role of LPG and proteophosphoglycans in UCNII-mediated killing using an inducible LPG system and a lpg2 mutant (unable to synthesize PGs) (25, 33) . UCNII showed the same leishmanicidal activities in wild-type parasites and both mutants (Fig. 5A) , suggesting that neither LPG nor PGs are required for UCNII activity.
Next, we determined the effect of pH and the essential sequence of the peptide with leishmanicidal activity. Decrease in the pH of growth media slightly reversed the parasiticidal effect of UCNII (Fig.  5B) . Moreover, UCNII-derived fragments UCNII 1-17 , UCNII [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , and UCNII were completely ineffective against L. major, and only UCNII showed some leishmanicidal activity (Fig. 5C ).
UCNII has leishmanicidal activity against intracellular forms of L. major
We next investigated the effect of UCNII on amastigotes, the infective intracellular stage of Leishmania. We infected mouse peritoneal macrophages with L. major promastigotes and evaluated the effect of UCNII during the infection, immediately after the entry of the parasite into the macrophage, or once that the parasite changes to the amastigote stage in the phagocytic vesicle. As expected, the exposition of the promastigote to UCNII in the extracellular space significantly reduced the infection capacity (Fig. 6Ai) . Notably, a potential therapeutic application was that UCNII reduced the parasite burden of L. major immediately after the infection of the macrophage (Fig. 6Aii) and even in the stage of amastigote (Fig. 6Aiii) . We envision two possibilities to explain the parasiticidal effect of UCNII on intracellular forms of L. major: 1) UCNII could favor the elimination of the parasite by improving the antimicrobial activity of the macrophage; 2) UCNII could exert directly its leishmanicidal activity inside the macrophage. To test the first possibility, we infected macrophages with L. major in the presence of inflammatory agents (LPS + IFN-g) and determined the secretion of inflammatory mediators. As expected, infection with L. major deactivated the inflammatory response of macrophages (Fig. 6B) . Treatment with UCNII did not affect the production of these cytotoxic effectors for intracellular amastigotes (Fig. 6B) . The second possibility implies the entry of UCNII into the macrophage and the intracellular interaction with the parasitophore vesicle. We observed that UCNII is initially localized in multiple intracellular vesicles of naive macrophages (Fig.  6C) , and then it accumulated in discrete vesicles surrounding and/or colocalizing with intracellular parasites (Fig. 6D) . Interestingly, parasites colocalizing with UCNII showed an altered morphology (Fig.  6D) , similar to that observed in vitro (Fig. 4B) . These findings indicate that UCNII has the capacity to enter into the infected macrophages, interacts with parasite-containing vesicles, and lyses them.
UCNII protects from cutaneous leishmaniasis
Next, we evaluated the capacity of UCNII to affect the susceptibility of BALB/c mice to L. major infection. Mice infected s.c. in the footpad with metacyclic promastigotes of L. major developed marked and progressive inflammatory edema and cutaneous lesions around the injected site (Fig. 7A ). Local treatment with UCNII reduced significantly paw swelling and lesion size (Fig.  7A) . UCNII treatment abolished the histopathological signs observed in the infected footpads characterized by extended areas of necrosis and ulceration in epidermis and destruction of cartilage and bone caused by a severe granulomatous inflammation as a consequence of the accumulation of parasite-infected macrophages in the dermis (Fig. 7B) . The protective effect of UCNII in leishmaniasis correlated with a striking decrease in the number of living parasites in cutaneous lesions (Fig. 7C) . Noteworthy was that UCNII completely prevented the systemic dissemination of this pathogen to immune and visceral organs (Fig. 7C) .
Host infections stimulate the production of UCNII Finally, we investigated whether the host responded to inflammation and/or infection by producing UCNII as part of its natural mechanism of defense. As Fig. 8A shows, the induction of sepsis significantly increased local (peritoneum) and systemic (blood) amounts of UCNII. Moreover, macrophages infected with bacteria or exposed to bacterial products (LPS) and inflammatory factors (IFN-g) secreted high and sustained levels of UCNII compared with naive macrophages (Fig. 8B) . Similarly, although cutaneous injection of L. major did not change serum levels of UCNII (Fig.  8C) , probably due to the local character of this infection, macrophages infected with this parasite secreted high amounts of UCNII (Fig. 8D, left) , especially in an inflammatory milieu (Fig.  8D, right) .
Discussion
Resurgence of infections with increasing resistance problems against conventional drugs and severe adverse effects due to current treatments highlight the urgent need for new strategies to combat microbial species. In the search for novel anti-infective therapies, cationic HDPs emerged as potential therapeutic candidates. In this study, we present evidence that the neuropeptide UCNII could be considered a HDP with potential therapeutic applications in the treatment of microbial infections. UCNII shares some structural and physicochemical characteristics with other antimicrobial peptides, including its small size and an amphipathic a-helical structure arranged in two clusters of hydrophobic residues flanking a central domain of cationic residues. These structural characteristics seem to give the selectivity of UCNII for pathogens versus mammalian cells and could explain the lack of antimicrobial effect shown by the related peptide UCNI. Like most of antimicrobial cationic peptides, UCNII recognizes and interacts with anionic residues exposed in the outer surface of bacteria and parasites, which clearly differs from the neutral membrane of mammalian cells. After its binding to pathogen surface, UCNII causes a disruption in its membrane, collapse in the intracellular ATP levels, and the subsequent death of the pathogen. However, our data indicate that the mechanisms involved in the killing effect of UCNII in bacteria and Leishmania differ slightly.
UCNII induces the depolarization of the bacterial membrane, apparently without the formation of disrupting pores. However, UCNII induces the retraction of the cytoplasmic membrane from the outer membrane, as occurs after sonication (34) . This effect could cause discrete lesions in the plasma membrane that allow permeation of ions, dissipation of ionic gradients across the membrane, and depolarization. This would be followed by a rapid bioenergetic collapse and bacteria killing. How UCNII induces these changes in bacteria surface is not fully known. In other antimicrobial peptides, the concentration of positive charges in the middle of the peptide flanked by two hydrophobic stretches predicts different stages of aggregation (35, 36) . As previously suggested (37), we found that UCNII forms aggregates. This process could have important consequences for its bactericidal effect. First, it would favor bacteria agglutination, an ancient mechanism of defense to neutralize pathogens that could contribute to the therapeutic effect shown by UCNII in sepsis by helping the clearance of bacteria at the focus of infection. Second, it would act as the mechanical force that leads to the retraction of the cytoplasmic membrane from the outer membrane. However, the increase in salt concentration did not affect UCNII aggregation state (data not shown), supporting the role played by the electrostatic interaction of UCNII with surface structures of bacteria. These processes imply the attachment of UCNII with one or various components of the bacteria surface. At the bacteria side, LPS emerges as a major target of UCNII. Interestingly, the heptose-rich domain of LPS was essential for the killing effect of UCNII on E. coli. At the other side, only the entire UCNII molecule fully retained the antibacterial activity, although the fragment containing the N-terminal hydrophobic domain and the central cationic cluster was partially effective. Therefore, we cannot rule out the involvement of the C-terminal domain of UCNII in the stabilization of the binding with LPS.
In the case of the parasite Leishmania, the cytolytic activity of UCNII implies damage of the plasma membrane through the induction of large-size lesions and probably the formation of disrupting pores, which is a death mechanism described for other leishmanicidal peptides (38) . Again, the fragment containing the Nterminal hydrophobic and central cationic clusters is essential and sufficient for the antiparasitic activity of UCNII. However, we were not able to identify the target of UCNII in the parasite surface. The plasma membrane of the promastigote stage possesses a thick anionic glycocalix made up mostly of LPG (39) . Using different mutants of L. major (25) , we demonstrated that neither LPG nor PGs are required for UCNII action. Interestingly, these mutants express LPG fragments and an abundant class of glycophosphatidylinositol lipids, which are present in promastigote and amastigote stages (39) and in bacterial LPS, suggesting that any of these molecules could be the target of UCNII. This could explain the cytolytic activity of UCNII against amastigotes, which, although downregulating the expression of LPG (and other surface macromolecules) and lacking a conspicuous surface coat, possess a plethora of GIPLs (39) . Moreover, glycophosphatidylinositol lipid structures differ among Leishmania species (40) (41) (42) , and this could potentially account for different susceptibility to UCNII found between Leishmania strains.
In our opinion, the effectiveness of UCNII against the intramacrophage amastigote form of the parasite is highly relevant from a therapeutic point of view. Few antimicrobial peptides with potent killing effects against the promastigote stage of the parasite are able to affect the infective form, and the mechanisms involved remain largely unknown (43) . In this study, we present evidence indicating that UCNII is able to enter in the macrophages through discrete vesicles, interacts with the parasitophorous vacuole, and apparently lyses the amastigote. Of note, the entry of UCNII into the infected macrophage affected neither the viability nor the inflammatory response of the host cell. UCNII could enter into the macrophage by a process of phagocytosis of the UCNII aggregates and/or via the internalization of UCNII-receptor complexes as a natural process of desensitization of the UCNII receptor exposed to high concentrations of the ligand. The microbicidal action of UCNII on intracellular amastigotes implies its effectiveness in the acidic milieu of the parasitophorous vacuole, presumably in a nonaggregated form. Our data suggest that, contrary to its effect on bacteria, the leishmanicidal effect of UCNII was independent of the formation of aggregates. Indeed, removal of the C-terminal domain responsible for the aggregation of UCNII did not affect its leishmanicidal activity. Therefore, the therapeutic effect of UCNII in cutaneous leishmaniasis must be mainly exerted by killing the intracellular infective forms, and probably by lysing the parasites released from infected cells reducing the density of the new infective population and dissemination of the disease to visceral organs.
Besides the therapeutic implications, our study is relevant from both physiological and evolutionary points of view. Of physiologic relevance is that host cells respond to microbial infection and inflammation by releasing UCNII as a natural mechanism of defense to counterbalance the ongoing insult. Our experiments focused on the production of UCNII by macrophages, as major players of the innate immunity. However, because UCNII is widely distributed in all body tissues, many other cells could contribute as UCNII source in vivo in conditions of infection. The fact that UCNII is especially abundant in physical barriers (gastrointestinal tract, respiratory tract, urinary tract, and skin) that are in constant contact with the pathogens (44) is important for its definition as HDP. Moreover, UCNII maintains the antimicrobial activities at pH and salt concentrations found in body fluids. In agreement with FIGURE 8. Endogenous UCNII production in response to inflammatory and/or infectious stimuli. (A) Induction of UCNII in septic mice. Mice (10/group) were subjected to CLP, and serum and peritoneal lavage were obtained 6 and 24 h after surgical procedure and assayed for UCNII content by a specific ELISA. **p , 0.001 versus sham. (B) Peritoneal macrophages were incubated with medium, LPS (100 ng/ml), LPS (100 ng/ml), plus IFN-g (5 ng/ml) or E. coli (10 6 cells). Levels of UCNII were determined by ELISA in culture supernatants collected at various time points. **p , 0.001 versus medium, three independent experiments. (C) BALB/c mice (20/group) were infected with metacyclic L. major, and the serum UCNII levels were determined at various time points postinfection. Uninfected animals were used as controls. (D) Peritoneal macrophages were infected with L. major (Lm) in the absence or presence of LPS (100 ng/ ml) plus IFN-g (5 ng/ml), and UCNII contents were determined in culture supernatants collected at various time points (24 h for right panel). n = 3 experiments. **p , 0.001 versus medium.
our data, mucosal samples of patients suffering inflammatory bowel disease and exposed to Clostridium difficile toxin A showed elevated UCNII levels (45) . Although the endogenous levels of UCNII produced during infection are some orders of magnitude lower than those required for an efficient in vitro antimicrobial activity, certain microenvironments may increase .10,000-fold the local amounts of other antimicrobial neuropeptides (46, 47) . Moreover, in vivo synergistic interactions of UCNII with other HDPs could potentate the overall antimicrobial activity (48) .
From an evolutionary perspective, UCNII belongs to one of the oldest peptide lineages conserved between species and regulates stress responses in endocrine, autonomic, and immune systems (49, 50) . Besides UCNIII, UCNII is the unique member of the CRH family that possesses structural features that are present in the single CRH-like peptide of tunicates and in the insect diuretic peptide (51) . Therefore, UCNII could be an ancient peptide derived from primitive diuretic peptides that has evolved as an endogenous neuropeptide, which is released to protect the host against a variety of stressful challenges, including microbial invasion.
In summary, UCNII emerges as an attractive candidate for clinical development as a single agent or in a combination therapy for combating several infectious disorders. Some advantages of using UCNII include its natural antimicrobial properties, selectivity, speed of action against pathogens, and low tendency to develop resistance, because it targets membrane components that are critical for the pathogen. Moreover, contrary to some current treatments, UCNII is not toxic for the host, as demonstrated by i.v. infusions of UCNII in healthy humans (52) . However, the potential therapeutic possibilities of UCNII imply some drawbacks concerning metabolic stability, bioavailability, and production cost that must be overcome.
With microbial drug resistance becoming a global public health problem, it is imperative to develop new anti-infective strategies. The concept of one drug with a single target and a single mode of action may not be correct. Innate immunity is a high defense system considering the frequency of infectious diseases despite our daily exposure to pathogens. Nature has chosen a different concept for the evolution of the innate host defense, favoring the appearance of compounds able to modulate many biological functions affecting the host and the pathogens. We might learn from evolution and develop novel drugs based on the design principles of these primitive and effective molecules.
